Ingersoll Rand IR Contingent Consideration Liability (Non-Current)

Contingent Consideration Liability (Non-Current) at other companies

Health CatalystHCAT

$156K-97.9%

ANI PharmaceuticalsANIP

$9.25M-46.9%

Steven MaddenSHOO

$15.27M+397%

BGSFBGSF

$249K-92.8%

TriSalus Life Sciences, Inc.TLSI

$2.74M-66.6%

KadantKAI

$2M—

Other financials

Income statement

See full

Revenue$1.8B+7.6%

Gross profit$792.4M+3.5%

Operating income$289.7M-4.2%

Net income$192.1M+3.0%

EPS (diluted)$0.49+6.5%

Balance sheet

See full

Cash & equivalents$1.3B-21.0%

Total debt$4.8B+0.2%

Total equity$10.2B-3.0%

Total assets$18.2B-0.9%

Cash flow

See full

Operating cash flow$199.7M-22.1%

CapEx$36.3M+7.7%

Free cash flow$163.4M-26.6%

Valuation

See full

Market cap$32.09B-10.2%

Enterprise value$35.65B-9.1%

P/E54.7×-13.7×

P/S4.1×-0.7×

Profitability

See full

Gross margin43.2%-0.6pp

Operating margin14.5%-3.4pp

Net margin7.5%-3.8pp

FCF margin14.9%-3.9pp

Returns & leverage

See full

Return on equity5.7%-2.4pp

Debt / equity0.5×0.0×

Current ratio2.2×-0.2×

Where this comes from

Reported directly by Ingersoll Rand in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.

The official record: Ingersoll Rand’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ingersoll Rand's contingent consideration liability (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ingersoll Rand's contingent consideration liability (non-current)?: Ingersoll Rand (IR) reported contingent consideration liability (non-current) of $32.4M in Q1 2026.